Company Overview
Snapshot
Founded in January 2013, Coramaze Technologies operates with 11–50 employees and has raised $6.26 million across 2 funding rounds from 4 investors. The company is currently in the clinical trial stage for its medical devices.
Business overview
Coramaze Technologies is a medical device company focused on developing innovative solutions for tricuspid valve disease. Its core product, Tripair, is designed as a percutaneous treatment to improve the quality of life and reduce morbidity for heart failure patients suffering from tricuspid regurgitation. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Coramaze Technologies' primary product?
- Coramaze Technologies develops the Tripair, a percutaneous treatment system for tricuspid valve disease, aimed at improving patient quality of life and reducing morbidity associated with tricuspid regurgitation.
- When was Coramaze Technologies founded?
- Coramaze Technologies was founded in January 2013.
- What is the current stage of Coramaze Technologies' product development?
- Coramaze Technologies' product, Tripair, is currently in the clinical trial stage.
- How much capital has Coramaze Technologies raised to date?
- Coramaze Technologies has raised a total of $6.26 million across its funding rounds.
- Which investors participated in Coramaze Technologies' A Round in September 2015?
- In September 2015, Coramaze Technologies secured an A Round with participation from. Elron Ventures was a lead investor in this round.